Mimir

Gene Therapies

Drug Approval Pipeline

Scope: Gene Therapies

As of August 2026, the FDA's approved cellular and gene therapy product list includes at least ABECMA and ADSTILADRIN, with the broader global approved gene therapy count standing at 75 products across the US, Europe, and Japan as of April 2024 (Journal of Community Genetics, 2025). The approval cadence has accelerated, with 8 new gene, cell, and RNA therapy approvals recorded in Q2 2026 alone — matching or exceeding prior quarterly totals — and mRNA-encoded CAR-T programs described as accelerating in the same period (ASGCT, 2025). IPD Analytics documented 17 cell and gene therapy candidates with potential for approval within a one-year horizon as of mid-2025, with estimated per-treatment costs ranging from $500,000 to $4 million; orphan gene therapies are documented as approximately 2–3.5 times more likely to receive FDA approval once reaching Phase 1 than other drug classes (IPD Analytics, 2025). The retrieved data does not provide individual drug names, sponsors, or specific regulatory phases for the 17 near-term pipeline candidates, limiting granular entry-level reporting.

Limitations: Pipeline status changes frequently; phase or pre-approval designation does not predict approval outcome or timing. The retrieved data identifies only two named approved products (ABECMA and ADSTILADRIN) and does not name, phase, or sponsor the 17 near-term pipeline candidates documented by IPD Analytics as of July 2025 — those entries cannot be individually represented without fabrication. The global approval count of 75 is specific to April 2024 data and may not reflect subsequent approvals. Approval cadence figures (Q1–Q2 2026) are sourced from an ASGCT report dated May 2025 and may reflect projections or early-year data rather than final confirmed counts. Regulatory status is jurisdiction-specific; data gaps exist for EMA and PMDA pipeline details. Verify current status via FDA, EMA, and trial registry filings directly.